Using our proprietary Enhanced Design and Combine (EDC) chemistry platform, we are developing an emerging portfolio of novel designer immunotherapies for the treatment of cancer and autoimmune diseases.
Using our proprietary Enhanced Design and Combine (EDC) chemistry platform, we are developing an emerging portfolio of novel designer immunotherapies for the treatment of cancer and autoimmune diseases.
Klybeckstrasse 191, 4057 Basel, Switzerland